Atypical femoral neck fracture after prolonged bisphosphonate therapy
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Of the drugs developed to prevent and treat osteoporosis, bisphosphonate has played a very important role in preventing osteoporotic fractures. However, case reports describing atypical femoral fractures in patients using long-term bisphosphonates have emerged. The majority of atypical femur fractures occurs in the lateral aspect of the subtrochanteric or femur diaphysis, which is explained by accumulation of tensile stress in these areas. Although the superior cortex of the femur neck withstands maximum tensile stress, to our knowledge, there have been only two reports (three cases) of atypical femoral neck fracture. In addition, none of those case reports revealed detailed pathology related to suppressed bone turnover rate. We encountered an incomplete femoral neck fracture and diagnosed it as “atypical” on the basis of the patient’s lack of trauma and medication history and pathological findings. For patients with groin pain, minimal or no trauma, and a history of long-term bisphosphonate use, an atypical femoral neck fracture should be considered.
Abstract
Of the drugs developed to prevent and treat osteoporosis, bisphosphonate has played a very important role in preventing osteoporotic fractures. However, case reports describing atypical femoral fractures in patients using long-term bisphosphonates have emerged. The majority of atypical femur fractures occurs in the lateral aspect of the subtrochanteric or femur diaphysis, which is explained by accumulation of tensile stress in these areas. Although the superior cortex of the femur neck withstands maximum tensile stress, to our knowledge, there have been only two reports (three cases) of atypical femoral neck fracture. In addition, none of those case reports revealed detailed pathology related to suppressed bone turnover rate. We encountered an incomplete femoral neck fracture and diagnosed it as “atypical” on the basis of the patient’s lack of trauma and medication history and pathological findings. For patients with groin pain, minimal or no trauma, and a history of long-term bisphosphonate use, an atypical femoral neck fracture should be considered.
참고문헌 (20)
- Shane E, "Atypical subtrochanteric and diaphyseal femoral fractures : report of a task force of the American Society for Bone and Mineral Research", J Bone Miner Res, 25, pp.2267~2294 (2010)
- Koh JS, "Distribution of atypical fractures and cortical stress lesions in the femur : implications on pathophysiology", Singapore Med J, 52, pp.77~80 (2011)
- Koch JC, "The laws of bone architecture", Am J Anat, 21, pp.177~298 (1917)
- 김도훈, "Insufficiency Fracture of Ipsilateral Femur Neck in Patient Treated with Long Term Bisphosphonate Treatment - A Case Report -", 대한골대사학회지, 19(2), pp.159~162 (2012), 대한골대사학회
- Khan SK, "Atraumatic intracapsular neck of femur fractures after prolonged bisphosphonate treatment : a new atypical variant", Clin Cases Miner Bone Metab, 13, pp.38~41 (2016)
- Schilcher J, "Histology of 8atypical femoral fractures : remodeling but no healing", Acta Orthop, 85, pp.280~286 (2014)
- Kajino Y, "Histological finding of atypical subtrochanteric fracture after long-term alendronate therapy", J Orthop Sci, 17, pp.313~318 (2012)
- Weinstein RS, "Giant osteoclast formation and long-term oral bisphosphonate therapy", N Engl J Med, 360, pp.53~62 (2009)
- Whyte MP, "Bisphosphonate-induced osteopetrosis", N Engl J Med, 349, pp.457~463 (2003)
- Jain N, "Giant osteoclasts after long-term bisphosphonate therapy : diagnostic challenges", Nat Rev Rheumatol, 5, pp.341~346 (2009)
- Lorget F, "High extracellular calcium concentrations directly stimulate osteoclast apoptosis", Biochem Biophys Res Commun, 268, pp.899~903 (2000)
- Nielsen RH, "Dissolution of the inorganic phase of bone leading to release of calcium regulates osteoclast survival", Biochem Biophys Res Commun, 360, pp.834~839 (2007)
- Rogers MJ, "Biochemical and molecular mechanisms of action of bisphosphonates", Bone, 49, pp.34~41 (2011)
- Cremers S, "Pharmacology of bisphosphonates", Bone, 49, pp.42~49 (2011)
- Parks TG, "Stress fractures of the neck of the femur", Ulster Med J, 39, pp.111~118 (1970)
- Bone HG, "Ten years’ experience with alendronate for osteoporosis in postmenopausal women", N Engl J Med, 350, pp.1189~1199 (2004)
- Greenblatt MB, "Bone turnover markers in the diagnosis and monitoring of metabolic bone disease", Clin Chem, 63, pp.464~474 (2017)
- Osada R, "Atypical ulnar fracture associated with long-term bisphosphonate use", J Orthop Sci, 20, pp.1132~1135 (2015)
- Breglia MD, "Atypical insufficiency fracture of the tibia associated with long-term bisphosphonate therapy", J Clin Rheumatol, 16, pp.76~78 (2010)
- Patel V, "Pelvic fractures associated with longterm bisphosphonate therapy-case report", J Musculoskelet Neuronal Interact, 13, pp.251~254 (2013)